Evidence map›Paper›PMID 28925795›Full record

ArticleHuman vaccines & immunotherapeutics2017

Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets.

Maryann Giel-Moloney, Michael Vaine, Linong Zhang, Mark Parrington, Beata Gajewska, Thorsten U Vogel, Svetlana O Pougatcheva, Xiaochu Duan, Timothy Farrell, Irina Ustyugova and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Maryann Giel-Moloneya R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Michael Vainea R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Linong Zhanga R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Mark Parringtona R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Beata Gajewskaa R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Thorsten U Vogela R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Svetlana O Pougatchevaa R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Xiaochu Duana R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Timothy Farrella R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Irina Ustyugovaa R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Sanjay Phogata R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Harry Kleanthousa R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Konstantin V Pugacheva R&D Discovery US, Sanofi Pasteur , Cambridge , MA , USA.
Sanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The RepliVax vaccine platform(RV) is based on flavivirus genomes that are rationally attenuated by deletion. The self-limiting infection provided by RV has been demonstrated to be safe, highly immunogenic and efficacious for several vaccine candidates against flaviviruses. Here respiratory syncytial virus (RSV) F, influenza virus HA, and simian immunodeficiency virus (SIV) Env proteins were expressed in place of either prM-E or C-prM-E gene deletions of the West Nile (WN) virus genome. The resulting RV-RSV, -influenza and -SIV vaccine prototypes replicated efficiently in complementing helper cells expressing the WN structural proteins in trans. Expressed antigens exhibited correct post-translational processing and the RV recombinants were shown to be highly attenuated and immunogenic in mice, eliciting strong antigen-specific antibodies as well as detectable T-cell responses. These data support the utility of RV vectors for development of vaccines against non-flavivirus targets including rabies and HIV.

Indexed as

Drug CarriersGenetic VectorsAnimalsAntibodies, ViralCytomegalovirusDefective VirusesGene ExpressionHemagglutinin Glycoproteins, Influenza VirusMice, Inbred BALB COrthomyxoviridaeSimian Immunodeficiency VirusT-LymphocytesT-Lymphocytes, Helper-InducerVaccines, SyntheticViral Envelope ProteinsViral Fusion ProteinsAntibodies, ViralDrug CarriersHemagglutinin Glycoproteins, Influenza VirusVaccines, SyntheticViral Envelope ProteinsViral Fusion ProteinsViral Vaccinesnon-flavivirus targetpreclinicalreplication-defectiveRepliVaxvaccine vector

Identifiers

PMID28925795
PMCPMC5718821
OpenAlexW2755638660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.